Analytical Data
-
Gene name
MYO7A
- Application
-
Alternative Names
MYO7A；USH1B；Unconventional myosin-VIIa
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13402
-
Expression Region
838-968aa
-
AA Sequence
WAVLTVQAYARGMIARRLHQRLRAEYLWRLEAEKMRLAEEEKLRKEMSAKKAKEEAERKHQERLAQLAREDAERELKEKEAARRKKELLEQMERARHEPVNHSDMVDKMFGFLGTSGGLPGQEGQAPSGFE
-
Molecular Weight
31.3kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYO7A (Myosin VIIA) is a member of the myosin superfamily of motor proteins, which play critical roles in cellular functions, including cargo transport, cell migration, and auditory processes. Mutations in the MYO7A gene are associated with various human conditions, including Usher syndrome type 1B, characterized by combined deafness and vision loss. Researchers have focused on the characterization and production of recombinant MYO7A protein to better understand its functional properties and the underlying mechanisms of disease. The ability to produce MYO7A as a recombinant protein allows for detailed biochemical and biophysical studies, including investigations into its structural dynamics and interaction with other cellular components. These studies are pivotal for developing therapeutic strategies aimed at mitigating the effects of MYO7A-related disorders. Furthermore, understanding the role of MYO7A in sensory cells, particularly in the inner ear and retina, can provide insights into potential regenerative medicine approaches. The elucidation of MYO7A's functional mechanisms through recombinant protein studies may open new avenues for interventions that could restore hearing and vision in affected individuals.
